Mode
Text Size
Log in / Sign up

Systemic corticosteroids associated with greater hearing gain than intratympanic therapy in idiopathic SSNHLSystemic steroids beat ear drops for sudden hearing loss

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that systemic corticosteroids are associated with greater hearing gain than intratympanic therapy in idiopathic SSNHL.

This single-center retrospective cohort study included 284 adults with idiopathic sudden sensorineural hearing loss (SSNHL) who had complete baseline and discharge audiometry. Participants were categorized by initial treatment: 240 received systemic corticosteroids (oral or IV) and 44 received intratympanic corticosteroids. The primary outcome was pure-tone average (PTA) gain, with secondary outcomes including complete recovery (≥30 dB gain) and effective improvement (≥15 dB gain). Follow-up duration was not reported.

Results indicated that systemic therapy was associated with greater PTA gain, with a crude mean difference of 13.8 dB for systemic therapy versus 3.8 dB for intratympanic therapy. The adjusted mean difference was 10.1 dB (95% bootstrap CI 1.8–19.5). Regarding complete recovery, systemic therapy was associated with a higher probability, showing an adjusted risk difference of 16.9% (95% CI 9.4–23.4). For effective improvement, the risk difference was 11.4% (95% CI −15.3 to 30.9).

Safety and tolerability data, including adverse events, discontinuations, and serious adverse events, were not reported. Key limitations include the observational nature of the study, which makes it vulnerable to confounding, particularly regarding post-treatment variables. Although weighting-based doubly robust estimators improved precision and matched analyses yielded consistent directions, uncertainty remained wider in matched analyses. Funding or conflicts of interest were not reported.

Clinicians should interpret these results as associations derived from real-world data rather than causal evidence from randomized trials. The findings may inform discussions regarding initial treatment choices, but the lack of safety data and potential for confounding necessitate cautious application in practice.

The Quiet Crisis

Imagine waking up and realizing you can't hear your favorite song. Maybe you can't hear your child calling your name. This is sudden sensorineural hearing loss, or SSNHL. It happens fast, often overnight. Doctors don't always know exactly why it occurs.

The condition is scary. It can happen to anyone. But it is most common in adults over 50. Many people feel helpless when this strikes. Current treatments are not perfect. Some doctors use steroids. But there is a debate about how to give them.

For years, doctors had two main choices. They could give steroids through a vein or by mouth. This is called systemic therapy. Or, they could inject the medicine directly into the ear canal. This is intratympanic therapy.

Many experts preferred the ear drops. They thought the medicine would go straight to the problem. But here is the twist. A new study suggests the opposite might be true. The old belief was that local delivery was safer and just as effective. This research changes that thinking.

Think of your inner ear like a busy city. Sound travels through specific pathways. When SSNHL hits, it is like a traffic jam blocking those pathways. Steroids act like a cleanup crew. They reduce swelling and inflammation.

The difference is where the crew enters. Systemic therapy sends the crew through the main highway (bloodstream) to reach the city. Intratympanic therapy sends a small team through a side door (the ear canal). The new study suggests the main highway gets more people to the destination.

Researchers looked at real patients, not just lab mice. They studied 284 adults between 2012 and 2019. Everyone had sudden hearing loss. They checked hearing before treatment and after discharge.

The team used special math to compare the two groups. They matched patients carefully to ensure fairness. This method removes bias. It shows what really happens in a hospital.

The results were clear. Patients who took systemic steroids heard better. Their hearing improved by an average of 13.8 decibels. Those who got ear drops improved by only 3.8 decibels.

That is a big difference. It means systemic therapy helped more people recover fully. About 17% more people got their hearing back to normal with the oral or IV route. The math is simple. One method works significantly better than the other.

But there's a catch. This is where things get interesting.

Doctors need to trust the data. This study used advanced statistical tools. These tools make the results more reliable. Experts say this fits with other real-world data. It suggests we should rethink our standard approach.

However, every patient is different. Some people might react differently. The study looked at a specific group. It did not test every possible cause of hearing loss.

If you or a loved one has sudden hearing loss, talk to your doctor. Ask about the treatment options. Do not assume ear drops are the only choice. Systemic steroids might be the better first step.

Remember, time is critical. You must see a doctor within 48 hours. The sooner you start treatment, the better the chance of recovery. Do not wait to see if it gets better on its own.

This study has limits. It was done at one hospital. It only looked at adults. It did not include children or people with known causes for hearing loss. Also, the study looked at short-term results. We do not know about long-term effects yet.

More research is needed. Scientists will look at larger groups of people. They will check if these results hold true everywhere. Regulatory bodies will review the data. They may update guidelines soon. Until then, doctors will weigh the options carefully. The goal is always to save hearing.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe optimal initial corticosteroid strategy for idiopathic sudden sensorineural hearing loss (SSNHL) remains uncertain, and randomized trials may not capture real-world variability. Observational comparisons are vulnerable to confounding, particularly when post-treatment variables are inappropriately adjusted. We evaluated the real-world comparative effectiveness of initial systemic versus intratympanic corticosteroids using a prespecified causal inference framework.MethodsWe conducted a retrospective cohort study (2012–2019) of adults with idiopathic SSNHL and complete baseline and discharge audiometry. Patients receiving combined systemic–intratympanic therapy or missing exposure data were excluded. The exposure was the initial corticosteroid route (systemic oral/IV vs. intratympanic). Propensity scores were estimated from baseline covariates including age, sex, symptom profile, comorbidities, baseline PTA, and time from symptom onset to treatment initiation. Primary estimation used augmented inverse probability of treatment weighting (AIPW) to retain all eligible patients; 1:1 propensity-score matching (caliper 0.2 SD of logit PS) with regression adjustment addressed residual imbalance as a sensitivity analysis. Outcomes were PTA gain (primary), complete recovery (≥30 dB gain), and effective improvement (≥15 dB gain).ResultsAmong 284 adults (systemic = 240; intratympanic = 44), crude mean PTA gain was 13.8 vs. 3.8 dB (difference 10.0 dB). In AIPW analysis, systemic therapy was associated with greater PTA gain (adjusted mean difference 10.1 dB; 95% bootstrap CI 1.8–19.5) and a higher probability of complete recovery (adjusted risk difference 16.9%; 95% CI 9.4–23.4). The risk difference for effective improvement was 11.4% (95% CI − 15.3 to 30.9). Findings were directionally consistent in IPTW, overlap-weighted, and matched analyses.ConclusionIn this single-center real-world cohort, initial systemic corticosteroids were associated with greater short-term hearing improvement and a higher likelihood of complete recovery compared with intratympanic therapy. Weighting-based doubly robust estimators improved precision and generalizability, while matched analyses yielded consistent direction but wider uncertainty.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.